S1602
|
SWOG
|
A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Nave High-Grade Non-Muscle Invasive Bladder Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1605
|
SWOG
|
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1607
|
SWOG
|
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma who have Progressed on ANTI-PD1/L1 Based Therapy
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1608
|
SWOG
|
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1609
|
SWOG
|
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1612
|
SWOG
|
A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1613
|
SWOG
|
A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1614
|
SWOG
|
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
|
Cancer Prevention and Control CIRB
|
Available to Open
|
|
S1616
|
SWOG
|
A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1619
|
SWOG
|
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|